Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RMP-A03 in Healthy Volunteers and Patients With Pterygium
NCT05794204Phase 2Completed
- Sponsor
- Suzhou Raymon Pharmaceuticals Co. Ltd.
- Start
- Jun 2023
- Primary completion
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of RMP-A03 in pterygium (3 arms), sponsored by Suzhou Raymon Pharmaceuticals Co. Ltd. Primary endpoint: Change From Baseline in Pterygium Hyperemia Grading at 28 days. Started Jun 2023; status: completed.
02
Drugs
RMP-A03
03
Conditions
pterygium
Beyond the preview
Go deeper on NCT05794204.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05794204.